0001193125-24-062878.txt : 20240308 0001193125-24-062878.hdr.sgml : 20240308 20240308071002 ACCESSION NUMBER: 0001193125-24-062878 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 24732322 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 8-K 1 d787565d8k.htm 8-K 8-K
false 0001658551 0001658551 2024-03-08 2024-03-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 8, 2024

 

 

AMYLYX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41199   46-4600503

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

43 Thorndike St.,

Cambridge, MA

  02141
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 682-0917

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   AMLX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 7.01

Regulation FD Disclosure.

On March 8, 2024, Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) issued a press release titled “Amylyx Pharmaceuticals Announces Topline Results from Global Phase 3 PHOENIX Trial of AMX0035 in ALS.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01

Other Events.

On March 8, 2024, the Company announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its primary endpoint of reaching statistical significance (p=0.667) as measured by change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score at Week 48, nor was there statistical significance seen in secondary endpoints. Amylyx plans to present the data from PHOENIX at an upcoming medical meeting and will publish the results in a medical journal later this year.

Amylyx will continue to engage with regulatory authorities and the broader ALS community to discuss the results from PHOENIX within the next eight weeks and make informed decisions. Amylyx intends to share plans for RELYVRIO/ALBRIOZA in ALS, which may include voluntarily withdrawing RELYVRIO/ALBRIOZA from the market. At this time, RELYVRIO/ALBRIOZA and its related patient support program will continue to be available for people living with ALS. Amylyx has voluntarily decided to pause promotion of the medication during this time.

Update on Ongoing AMX0035 Studies

The global, randomized, double-blind, placebo-controlled Phase 3 ORION clinical study of AMX0035 in PSP remains ongoing. The first participant was dosed in December 2023, and the Company is planning for an interim analysis. Topline results continue to be anticipated in 2025 or 2026. Data from the ongoing 12-participant, single site, open-label Phase 2 HELIOS clinical study are demonstrating evidence of clinical activity of AMX0035 in Wolfram syndrome. This study is fully recruited, and the Company plans to present preliminary data in the second quarter of 2024.

Forward-Looking Statements

Statements contained in this Current Report on Form 8-K and related comments in our investor conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx’ expectations regarding: interactions with regulatory authorities; the continued availability of RELYVRIO/ALBRIOZA for people living with ALS while such interactions are ongoing; the pausing of promotion of RELYVRIO/ALBRIOZA; pathways for continued access for patients if RELYVRIO/ALBRIOZA are withdrawn from the market; the possibility for Amylyx to voluntarily withdraw RELYVRIO/ALBRIOZA from the market; the continued evaluation of AMX0035 in other neurodegenerative diseases, including the timing for expected data readouts in the ORION and HELIOS studies; and the evidence of biological activity of AMX0035 in Wolfram syndrome. Any forward-looking statements in this Form 8-K and related comments in the Company’s conference call are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include the risks and uncertainties set forth in Amylyx’ United States Securities and Exchange Commission (SEC) filings, including Amylyx’ Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements


contained in this Form 8-K and related comments in our conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number
  

Description

99.1    Press Release of the Company, dated March 8, 2024
104    Cover Page Interactive Data File (embedded with the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    AMYLYX PHARMACEUTICALS, INC.
Date: March 8, 2024     By:  

/s/ James M. Frates

      James M. Frates
      Chief Financial Officer
EX-99.1 2 d787565dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX

Trial of AMX0035 in ALS

-  PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints

-  Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated

-  Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Community to Share Topline Data; Amylyx Will Share Plans for RELYVRIO/ALBRIOZA in ALS Which May Include Voluntarily Withdrawing RELYVRIO/ALBRIOZA From the Market

-  At This Time, RELYVRIO/ALBRIOZA Will Continue to be Available for People Living With ALS; Amylyx Has Voluntarily Decided to Pause Promotion; Related Patient Support Services Will Remain in Place

-  Studies With AMX0035 in Wolfram Syndrome (WS) and Progressive Supranuclear Palsy (PSP) to Continue Based on Data Supporting its Potential in These Diseases

-  Amylyx to Host Investor Conference Call Today, March 8, at 8:00 a.m. ET

CAMBRIDGE, Mass. March 8, 2024 — Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA in Canada) in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its primary endpoint of reaching statistical significance (p=0.667) as measured by change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score at Week 48, nor was there statistical significance seen in secondary endpoints. Amylyx plans to present the data from PHOENIX at an upcoming medical meeting and will publish the results in a medical journal later this year.

Amylyx will continue to engage with regulatory authorities and the broader ALS community, including ALS specialists and other multidisciplinary experts, people living with ALS, and advocates, to discuss the results from PHOENIX within the next eight weeks and make informed decisions. Amylyx intends to share plans for RELYVRIO/ALBRIOZA in ALS, which may include voluntarily withdrawing RELYVRIO/ALBRIOZA from the market. At this time, RELYVRIO/ALBRIOZA and its related patient support program will continue to be available for people living with ALS. Amylyx has voluntarily decided to pause promotion of the medication during this time.

“We are surprised and deeply disappointed by the PHOENIX results following the positive data from the CENTAUR trial. Our main priority at the moment is sharing the information with people living with ALS and their treating physicians; this is part of our continued commitment to them and our mission. Over


the next eight weeks, our team will continue to engage with regulatory authorities and the ALS community to discuss the results from PHOENIX. We will be led in our decisions by two key principles: doing what is right for people living with ALS, informed by regulatory authorities and the ALS community, and by what the science tells us. On behalf of the entire Amylyx team, we are grateful to the ALS community and for the dedication of trial participants, investigators, and study site teams. With data collected from 664 participants in PHOENIX, we are certain there will be important learnings that will help inform future ALS research. We are steadfast in our commitment to the ALS community and our mission, including with AMX0035 where it has shown potential in neurodegenerative diseases such as Wolfram syndrome and progressive supranuclear palsy, and with AMX0114, our investigational antisense oligonucleotide targeting calpain-2, in ALS,” said Justin Klee and Joshua Cohen, Co-CEOs of Amylyx.

PHOENIX Study Results:

The Phase 3 PHOENIX study enrolled 664 adults living with ALS. Participants were randomized three-to-two to receive either AMX0035 or placebo, with both treatment groups receiving standard-of-care. Continuation of a stable dosing regimen of riluzole and/or edaravone was permitted.

 

   

PHOENIX did not meet the primary endpoint: There was no significant difference observed between participants treated with AMX0035 and placebo in ALSFRS-R total score change from baseline at Week 48 (p=0.667). No significant difference was observed in the subset of participants who met the CENTAUR trial criteria. There were also no significant differences observed across secondary endpoints.

 

   

Consistent safety and tolerability profile: AMX0035 was well-tolerated in PHOENIX. There were no new safety signals, reinforcing the favorable and manageable safety profile observed with AMX0035 to date.

 

   

European participants who completed the 48-week randomized phase had the option to enroll in an open label extension of the trial of up to two years in duration, which remains ongoing.

Science of AMX0035:

AMX0035, a specially formulated oral fixed-dose combination of PB and TURSO, has been shown in numerous preclinical studies to have a robust, synergistic effect in targeting two different destructive neurodegenerative disease pathways by mitigating endoplasmic reticulum stress and the associated unfolded protein response and mitochondrial dysfunction thereby reducing neuronal cell death. Additionally, AMX0035 has been shown to also reduce markers associated with neurodegenerative diseases in clinical trials, including a reduction of tau, a key protein aggregate shared across several neurodegenerative diseases, and YKL-40, a marker of neuroinflammation.

Update on Ongoing AMX0035 Studies:

The global, randomized, double-blind, placebo-controlled Phase 3 ORION clinical study of AMX0035 in PSP remains ongoing. The first participant was dosed in December 2023, and the Company is planning for an interim analysis. Topline results continue to be anticipated in 2025 or 2026.


Data from the ongoing 12-participant, single site, open-label Phase 2 HELIOS clinical study are

demonstrating evidence of clinical activity of AMX0035 in Wolfram syndrome. This study is fully recruited, and the Company plans to present preliminary data in the second quarter of 2024.

##

Investor Conference Call Information

Amylyx’ management team will host a live conference call and webcast today, March 8, 2024, at 8:00 a.m. ET to discuss the results of the PHOENIX trial. To participate in the conference call, please dial +1 (877) 870-4263 (U.S.), +1 (855) 669-9657 (Canada), or +1 (412) 317-0790 (International) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. All interested parties are invited to access a live broadcast of the call via a webcast, which will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at investors.amylyx.com/news-events/events. An archived webcast will be available on the Company’s website approximately two hours after the conference call and will be available for replay for 90 days following the call.

About the PHOENIX Trial

PHOENIX was a 48-week, randomized, placebo-controlled, global Phase 3 clinical trial further evaluating the safety and efficacy of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of ALS. The primary efficacy outcome of the trial was change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) total score at 48 weeks. Secondary endpoints include quality of life patient-reported outcome assessments, overall survival, and respiratory function as measured by slow vital capacity (SVC). Safety and tolerability were also assessed.

European participants who completed the 48-week trial had the option to enroll in an open-label extension (OLE) phase. During this phase, all participants receive AMX0035, and continued safety and efficacy measures will be assessed.

About the CENTAUR Trial

CENTAUR was a multicenter Phase 2 clinical trial in 137 participants with ALS encompassing a 6-month randomized, placebo-controlled phase and an open-label long-term follow-up phase. The trial met its primary efficacy endpoint of reducing functional decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R).

Overall, reported rates of adverse events and discontinuations were similar between AMX0035 and placebo groups during the 24-week randomized phase; however, gastrointestinal events occurred with greater frequency (≥2%) in the AMX0035 group. Detailed data from CENTAUR is published in the New England Journal of Medicine (NEJM) and Muscle & Nerve.


The CENTAUR trial was funded, in part, by the ALS ACT grant and the ALS Ice Bucket Challenge, and was supported by The ALS Association, ALS Finding a Cure (a program of The Leandro P. Rizzuto Foundation), the Northeast ALS Consortium, and the Sean M. Healey & AMG Center for ALS at Mass General.

About AMX0114

AMX0114 is an antisense oligonucleotide designed to target the gene encoding calpain-2, a key contributor to the axonal (Wallerian) degeneration pathway. Axonal degeneration has been recognized as an important early contributor to the clinical presentation and pathogenesis of ALS and other neurodegenerative diseases. Calpain-2 has been implicated in the pathogenesis of ALS based on findings of elevated levels of calpain-2 and its cleavage products in postmortem ALS tissue, therapeutic benefit of calpain-2 modulation in animal models of ALS, and the role of calpain-2 in cleaving neurofilament, a broadly researched biomarker in ALS. Preclinical studies completed to date have shown that AMX0114 achieves potent, dose-dependent, and durable knockdown of CAPN2 mRNA expression and calpain-2 protein levels in human motor neurons. Moreover, in preclinical efficacy studies, treatment with AMX0114 reduced extracellular neurofilament light chain levels following neurotoxic insult in iPSC-derived human motor neurons, and improved survival of iPSC-derived human motor neurons harboring ALS-linked, pathogenic TDP-43 mutations.

About ALS

Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than 90% of people with ALS have sporadic disease, showing no clear family history. ALS affects around 30,000 people in the U.S., and more than 30,000 people are estimated to be living with ALS in Europe (European Union and United Kingdom). People living with ALS have a median survival of approximately two years from diagnosis.

About HELIOS

The HELIOS trial (NCT05676034) is a 12-participant, open-label proof of biology, Phase 2 trial designed to study the effect of AMX0035 on safety and tolerability, and various measures of endocrinological, neurological, and ophthalmologic function in adult participants living with Wolfram syndrome (WS).

About Wolfram Syndrome

Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy, and neurodegeneration. Common manifestations of WS include diabetes mellitus, optic nerve atrophy, central diabetes insipidus, sensorineural deafness, neurogenic bladder, and progressive neurologic difficulties. Genetic and experimental evidence suggest that endoplasmic reticulum (ER) dysfunction is a critical pathogenic component of WS. The prognosis of WS is poor, and many people with the disease die prematurely with severe neurological disabilities.


About the ORION Trial

The Phase 3 ORION trial (NCT06122662) is a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 compared to placebo in people living with progressive supranuclear palsy (PSP). The ORION Phase 3 trial was designed and planned in collaboration with key global academic leaders, people living with PSP and their caregivers, and industry advocacy organizations.

About PSP

Progressive supranuclear palsy (PSP) is a sporadic, rare and adult-onset neurodegenerative disorder that affects walking and balance, eye movement, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis, and its epidemiology is similar to that of amyotrophic lateral sclerosis (ALS). PSP typically begins in late-middle age and rapidly progresses over time. The disease affects approximately seven in 100,000 people worldwide, and there are currently no disease-modifying therapies approved for the treatment of PSP.

PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy. Similar to other neurodegenerative diseases, pathophysiologic changes underlying PSP are multifactorial with several genetic and environmental factors likely contributing to tau dysfunction and aggregation.

Multiple pathways, including genetic mutations, endoplasmic reticulum (ER) stress and the activation of unfolded protein response, mitochondrial dysfunction, and neuroinflammation have been implicated as contributors to tau dysfunction and aggregation.

About AMX0035 / RELYVRIO®/ ALBRIOZA

AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol (known as ursodoxicoltaurine outside of the U.S.). It is approved as RELYVRIO® to treat amyotrophic lateral sclerosis (ALS) in adults in the U.S. and approved with conditions as ALBRIOZA for the treatment of ALS in Canada. AMX0035 is being studied for the potential treatment of other neurodegenerative diseases, and Amylyx is exploring its treatment in other populations and regions. The formulation of RELYVRIO, ALBRIOZA, and AMX0035 is identical.

RELYVRIO® (sodium phenylbutyrate and taurursodiol) Safety Information for United States

WARNINGS AND PRECAUTIONS

Risk in Patients with Enterohepatic Circulation Disorders, Pancreatic Disorders, or Intestinal Disorders

RELYVRIO contains taurursodiol, which is a bile acid. In patients with disorders that interfere with bile acid circulation, there may be an increased risk for worsening diarrhea, and patients should be monitored appropriately for this adverse reaction. Pancreatic insufficiency, intestinal malabsorption, or intestinal diseases that may alter the concentration of bile acids may also lead to decreased absorption of either of the components of RELYVRIO. Because different enterohepatic circulation, pancreatic, and


intestinal disorders have varying degrees of severity, consider consulting with a specialist. Patients with disorders of enterohepatic circulation (e.g., biliary infection, active cholecystitis), severe pancreatic disorders (e.g., pancreatitis), and intestinal disorders that may alter concentrations of bile acids (e.g., ileal resection, regional ileitis) were excluded from the study; therefore, there is no clinical experience in these conditions.

Use in Patients Sensitive to High Sodium Intake

RELYVRIO has a high salt content. Each initial daily dosage of 1 packet contains 464 mg of sodium; each maintenance dosage of 2 packets daily contains 928 mg of sodium. In patients sensitive to salt intake (e.g., those with heart failure, hypertension, or renal impairment), consider the amount of daily sodium intake in each dose of RELYVRIO and monitor appropriately.

ADVERSE REACTIONS

The most common adverse reactions (at least 15% and at least 5% greater than placebo) with RELYVRIO were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. Gastrointestinal-related adverse reactions occurred throughout the study but were more frequent during the first 3 weeks of treatment.

Please click here for RELYVRIO Full U.S. Prescribing Information.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada, EMEA, and Japan. For more information, visit amylyx.com and follow us on LinkedIn and X, (formerly Twitter). For investors, please visit investors.amylyx.com.

Forward-Looking Statements

Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx’ expectations regarding: interactions with regulatory authorities; the continued availability of RELYVRIO/ALBRIOZA for people living with ALS while such interactions are ongoing; the pausing of promotion of RELYVRIO/ALBRIOZA; pathways for continued access for patients if RELYVRIO/ALBRIOZA are withdrawn from the market; the possibility for Amylyx to voluntarily withdraw RELYVRIO/ALBRIOZA from the market; the continued evaluation of AMX0035 in other neurodegenerative diseases, including the timing for expected data readouts in the ORION and HELIOS studies; and the evidence of biological activity of AMX0035 in Wolfram syndrome. Any forward-looking statements in this press release and related comments in the Company’s conference call are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ


materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include the risks and uncertainties set forth in Amylyx’ United States Securities and Exchange Commission (SEC) filings, including Amylyx’ Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media

Amylyx Media Team

(857) 799-7274

amylyxmediateam@amylyx.com

Investors

Lindsey Allen

(857) 320-6244

Investors@amylyx.com

EX-101.SCH 3 amlx-20240308.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 amlx-20240308_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 amlx-20240308_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 08, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001658551
Document Type 8-K
Document Period End Date Mar. 08, 2024
Entity Registrant Name AMYLYX PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-41199
Entity Tax Identification Number 46-4600503
Entity Address, Address Line One 43 Thorndike St.
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code (617)
Local Phone Number 682-0917
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol AMLX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports amlx-20240308.xsd amlx-20240308_lab.xml amlx-20240308_pre.xml d787565d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d787565d8k.htm": { "nsprefix": "amlx", "nsuri": "http://www.amylyx.com/20240308", "dts": { "schema": { "local": [ "amlx-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "amlx-20240308_lab.xml" ] }, "presentationLink": { "local": [ "amlx-20240308_pre.xml" ] }, "inline": { "local": [ "d787565d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-08_to_2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d787565d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-08_to_2024-03-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d787565d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.amylyx.com//20240308/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-062878-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-062878-xbrl.zip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end XML 16 d787565d8k_htm.xml IDEA: XBRL DOCUMENT 0001658551 2024-03-08 2024-03-08 false 0001658551 8-K 2024-03-08 AMYLYX PHARMACEUTICALS, INC. DE 001-41199 46-4600503 43 Thorndike St. Cambridge MA 02141 (617) 682-0917 false false false false Common Stock, $0.0001 par value per share AMLX NASDAQ false